{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-380194","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2026-09-02T20:11:16+00:00","discovered_at":"2026-09-02T20:12:01.294053+00:00","generated_at":"2026-09-02T20:12:07.854062+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cogent Biosciences signs 5-year supply deal with Hovione for bezuclastinib manufacturing","bullets":["Agreement with Hovione FarmaCiencia S.A. covers bezuclastinib spray-dried dispersion and tablets.","Initial 5-year term with automatic 2-year renewals; minimum purchase percentages decrease over time.","Quarterly forecasts; near-term portion binding, balance non-binding good-faith estimates.","Termination rights include uncured breach, prolonged force majeure, insolvency, regulatory developments.","Full agreement to be filed with Q3 2026 Form 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-380194","json":"https://secwatch.observer/filing/0001193125-26-380194.json","markdown":"https://secwatch.observer/filing/0001193125-26-380194.md","text":"https://secwatch.observer/filing/0001193125-26-380194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/0001193125-26-380194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/d184156d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-02T20:12:07.854062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}